2017
DOI: 10.4045/tidsskr.17.0620
|View full text |Cite
|
Sign up to set email alerts
|

Developing a vaccine for leishmaniasis: how biology shapes policy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…Additionally, the available CL treatment is highly toxic and not fully effective (Caridha et al, 2019). A range of factors could explain the lack of vaccines and therapeutic options against CL, like the diversity among Leishmania species and the complexity of host's immune responses (Müller et al, 2018;Kaye et al, 2020). Thus, understanding the effective immune response to Leishmania infection is fundamental to benefit the processes of drug discovery and vaccine development.…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, the available CL treatment is highly toxic and not fully effective (Caridha et al, 2019). A range of factors could explain the lack of vaccines and therapeutic options against CL, like the diversity among Leishmania species and the complexity of host's immune responses (Müller et al, 2018;Kaye et al, 2020). Thus, understanding the effective immune response to Leishmania infection is fundamental to benefit the processes of drug discovery and vaccine development.…”
Section: Introductionmentioning
confidence: 99%